BIOTRICITY INC. (BTCY): Nasdaq/NYSE listing notice — Biotricity receives Nasdaq bid price deficiency notice; 180 days to cure

BIOTRICITY INC.

Nasdaq letter on Jan 20, 2023: closing bid price below $1.00 for 30 consecutive days.
Company has until July 19, 2023 to regain compliance with Bid Price Rule.
To regain compliance, bid must close at $1.00+ for 10 consecutive business days.
If not compliant by deadline, Nasdaq may delist; company may consider reverse stock split.
No immediate effect on listing or trading of BTCY common stock.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIOTRICITY INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 20, 2023, Biotricity Inc. (the “Company”), received a letter (the “Letter”) from the staff of The Nasdaq Capital Market LLC (the “NasdaqCapital Market”) stating that the Company’s closing bid price for the last 30 consecutive business days was less than $1.00 per share. As a result, the Company does not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification had no immediate effect on the listing or trading of the common stock on the Nasdaq Capital Market. Nasda

View on SEC.gov

Browse all listing & compliance notices →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-002082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.